Karuna Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies to address disabling neuropsychiatric conditions. The company lead product, KarXT, is an oral modulator of muscarinic receptors. It specializes in research, development, commercialization of numerous central neural system agents and products targeted at a broad range of psychiatric and neurological conditions.
|Employees (est.) (Jul 2019)||16|
|Share Price (Oct 2019)||$13.4||(+18%)|
EBIT (Q2, 2019)
Market capitalization (16-Oct-2019)
Closing stock price (16-Oct-2019)
Karuna Therapeutics has 52 Twitter Followers. The number of followers has increased 9.5% month over month and increased 11.1% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Karuna Therapeutics founded?
Karuna Therapeutics was founded in 2009.
Who are Karuna Therapeutics key executives?
Karuna Therapeutics's key executives are Steve Paul, Stephen Brannan and Andrew Miller.
How many employees does Karuna Therapeutics have?
Karuna Therapeutics has 16 employees.
Who are Karuna Therapeutics competitors?
Competitors of Karuna Therapeutics include Jour, Nori Health and One Medical Group.
Where is Karuna Therapeutics headquarters?
Karuna Therapeutics headquarters is located at 33 Arch Street, Boston.
Where are Karuna Therapeutics offices?
Karuna Therapeutics has an office in Boston.
How many offices does Karuna Therapeutics have?
Karuna Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies